LEXINGTON, Mass.-- (BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results